Introduction {#s1}
============

Patients with COPD experience a progressive worsening of activity-related breathlessness, which can severely impact their daily lives \[[@C1]--[@C3]\]. Due to the discomfort experienced, patients often avoid engaging in physical activity. This has been associated with further deconditioning, decreased exercise capacity and more rapid disease progression, often resulting in an impaired ability to engage in daily activities and significant psychological distress \[[@C4]\].

The clinical management of COPD includes a combination of pharmacotherapy and pulmonary rehabilitation \[[@C5]\]. However, the effectiveness of these treatments relies upon the patient\'s ability to understand and adhere to prescribed interventions, which may be compromised in patients with COPD due to psychological factors and cognitive limitations. Poor psychosocial adaptation to having COPD, feelings of helplessness and fear/panic in response to breathlessness, and exertional breathlessness that is not relieved by medication are thought to contribute to heightened levels of psychological distress in this population \[[@C6], [@C7]\]. Symptoms of both depression and anxiety have been associated with diminished exercise performance, less participation in pulmonary rehabilitation and an increased risk of exacerbations \[[@C8]--[@C10]\].

Cognitive impairments have been shown to affect patients with COPD with a significantly higher frequency than is observed among age-matched controls \[[@C11], [@C12]\]. Cognitive impairments in patients with COPD may result from both pulmonary (*e.g.* hypoxia, hypercapnia and exacerbations) and nonpulmonary factors (*e.g.* decreased physical activity) that tend to worsen as the disease progresses \[[@C13], [@C14]\]. The cognitive impairments observed tend to affect attention, working memory, executive function (judgement and reasoning), psychomotor speed, language skills and complex visual--motor processes \[[@C15], [@C16]\]. The presence of cognitive impairments has also been shown to interfere with several aspects of treatment adherence and self-management among patients with COPD, including inhaler compliance and participation in pulmonary rehabilitation \[[@C17], [@C18]\].

There is a need to explore treatments that could lead to improvements in psychological and cognitive functioning among patients with COPD. There is evidence linking exercise (any planned, structured and repetitive movement designed to improve or maintain fitness) and physical activity (any bodily movement leading to energy expenditure) to improvements in depression and anxiety in patients with psychiatric \[[@C19]\] and chronic disease \[[@C20]\]. Exercise and physical activity have also been associated with slower rates of cognitive decline and improvements in cognitive function in both healthy subjects \[[@C21]\] and those with chronic disease \[[@C22]\], as well as in those with mild cognitive impairment \[[@C23]\] and dementia \[[@C24]\]. A recent trial highlighted the positive effects of exercise training (ExT) on cognitive function in patients with COPD \[[@C25]\]. However, the relative impact of ExT *versus* engaging in regular daily activities on psychological and cognitive functioning in patients with COPD has not been explored.

The PHYSACTO trial assessed the effects of a multimodal approach to COPD treatment \[[@C26]--[@C28]\], focusing on whether tiotropium/olodaterol (T/O), with or without ExT, would improve exercise endurance time (EET) and physical activity compared with placebo in patients participating in an self-management behaviour modification (SMBM) programme ([figure 1](#F1){ref-type="fig"}). Psychological variables (*i.e.* levels of depressive and anxiety symptoms, and rates of clinically significant depression), and cognitive function pre- and post-treatment were also measured. This substudy aimed to evaluate treatment effects on both psychological and cognitive functioning. We hypothesised that psychological and cognitive functioning would improve significantly from pre- to post-treatment in all treatment arms, with the greatest improvements seen in those also receiving ExT (SMBM+T/O+ExT). We expected improvements in psychological and cognitive functioning would be positively correlated with actual/observed improvements in exercise capacity and physical activity.

![Study design. Black circles represent behavioural modification sessions. V: visit; BM: behavioural monitoring; AM: activity monitoring; ExT: exercise training; SMBM: self-management behavioural modification; T: tiotropium; O: olodaterol.](00013-2019.01){#F1}

Methods {#s2}
=======

Study design {#s2a}
------------

Full details of the study design have been previously published \[[@C26]--[@C28]\]. PHYSACTO (study 1237.16; [www.clinicaltrials.gov](http://www.clinicaltrials.gov) identifier number NCT02085161) was a 12-week, randomised, partially double-blind, placebo-controlled, parallel-group trial in patients with COPD. All pharmacological treatments were administered in a blinded manner, except for participants and staff in the group receiving ExT. The study was conducted in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonized Tripartite Guideline for Good Clinical Practice. The study complied with all Institutional Review Board, independent ethics committee, and national and international competent authority regulations. All patients were required to provide written, informed consent prior to participation.

Interventions {#s2b}
-------------

Details of the interventions have been published elsewhere \[[@C27]\]. Briefly, all patients participated in a 12-week SMBM programme adapted from the Living Well with COPD programme \[[@C29]\] delivered using a motivational communication style that aimed to increase patients\' motivation and confidence in their ability to engage in higher levels of daily physical activity \[[@C26]\]. This programme was delivered by carefully selected case managers that received standardised training from and supervision by the global behaviour modification team (K.L. Lavoie, J. Bourbeau and M. Sedeno). Case managers used evidence-based behaviour change techniques (*e.g.* goal setting, problem solving and positive reinforcement), which were delivered using a motivational communication style that was patient-centred and adapted to patients\' levels of readiness for change \[[@C30]\]. Patients were randomly assigned (1/1/1/1) to 12 weeks of once-daily tiotropium 5 µg (SMBM+T), T/O 5/5 µg (SMBM+T/O), T/O 5/5 µg plus ExT (SMBM+T/O+ExT) or placebo (SMBM+P), all using the Respimat device after a 4-week washout period. Patient inclusion and exclusion criteria have been previously published \[[@C26]\].

Outcomes {#s2c}
--------

### Primary and secondary outcomes of the main trial {#s2c1}

The primary outcome of the PHYSACTO trial \[[@C28]\] was EET (seconds) during an endurance shuttle walk test (ESWT) to symptom limitation after 8 weeks, reflecting the duration of the ExT programme \[[@C27]\]. The secondary outcome was levels of daily physical activity, measured according to step counting using a triaxial accelerometer (DynaPort MoveMonitor; McRoberts, The Hague, The Netherlands). Average number of steps per day and average daily walking time were used as measures of physical activity, and gravitational acceleration (1×*g*=9.81 m·s^−2^) was used to measure physical activity intensity. Distance walked during the 6-min walk test (6MWT) was included as a secondary endpoint to assess walking capacity during self-paced walking. The 6MWT was performed 3 h after inhalation of study medication at weeks 8 and 12 (*i.e.* 1 h after the ESWT). These results have been published elsewhere and will not be re-reported here \[[@C28]\].

### Psychological and cognitive outcomes {#s2c2}

The primary outcomes of interest in this study were depression and anxiety levels, likely "caseness" of major depressive disorder, and cognitive function.

#### Hospital Anxiety and Depression Scale {#s2c2a}

The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report questionnaire that assesses the previous week\'s symptoms of depression and anxiety. The depression (HADS-D) and anxiety (HADS-A) subscales each include seven questions rated on a four-point scale from 0 to 3 (range 0--42), where scores ≥8 are considered clinically significant \[[@C31], [@C32]\]. The HADS has demonstrated excellent psychometric properties, including a Cronbach\'s *α* coefficient of 0.91 in patients with COPD.

#### Patient-Health Questionnaire-9 {#s2c2b}

The Patient-Health Questionnaire (PHQ)-9 is a self-report questionnaire designed to assess clinical symptoms of major depressive disorder (MDD) according to *Diagnostic and Statistical Manual of Mental Disorders* (4th Edn) criteria. It includes nine questions rated on a scale from 0 to 3 (range 0--27), where scores ≥5 are considered the lower limit of clinically significant MDD symptoms. The PHQ-9 has excellent psychometric properties, including sensitivity and specificity of 88% for MDD associated with scores \>10 \[[@C33]\].

#### Montreal Cognitive Assessment Test {#s2c2c}

The Montreal Cognitive Assessment Test (MoCA) is a rapid screening tool for mild cognitive dysfunction. It assesses various domains, including executive function, attention, concentration, language, memory, visuospatial skills, abstract thinking and orientation. The MoCA is validated for use among adults aged 55--85 years, has high test--retest reliability (with no significant learning effects when administered at 3-month intervals) and good internal consistency \[[@C34]\]. The maximum score on the MoCA is 30, with scores ≥26 denoting normal cognitive functioning and scores \<26 denoting the lower cut-off for mild cognitive impairment \[[@C34]\].

Questionnaires were used as a part of the behavioural modification intervention to assess cognitive function, level of depression and anxiety. They were completed at visit 1 (baseline or 4 weeks before treatment initiation), and then repeated at visits 5 (after 8 weeks of treatment and 12 weeks post-baseline) and 8 (after 12 weeks of treatment and 16 weeks post-baseline).

Statistical analyses {#s2d}
--------------------

Baseline characteristics were compared for the four treatment groups using ANOVA or the Kruskal--Wallis test for continuous variables, and the Chi-squared test for categorical variables. To assess the changes of psychological and cognitive outcomes after 12 weeks of treatment, generalised estimating equations with a repeat statement and an unstructured correlation structure were performed, using a normal distribution for continuous outcomes with an identity link and binomial distributions for categorical outcomes with a logarithmic link. This approach accounts for the correlation of measures at different time-points. All continuous outcomes were classified as categorical variables based on minimal clinically important difference scores; models were selected based on normal distributions for continuous outcomes with an identity link and binomial distributions for categorical outcomes with a logarithmic link. Tukey adjustment for multiple comparisons were also performed for significant overall p-values. Mixed-effects linear models were used to estimate the relationship between physical activity, exercise capacity, and psychological and cognitive outcomes, with random intercepts to capture individual-specific change, adjusted for covariates. All analyses were performed using SAS, version 9.4 (SAS Institute, Cary, NC, USA); p-values \<0.05 were considered statistically significant.

Results {#s3}
=======

Sample characteristics {#s3a}
----------------------

Baseline characteristics were generally balanced between groups ([table 1](#TB1){ref-type="table"}). Patients were 66% male and mean±[sd]{.smallcaps} age was 65±6.6 years. 37% were current smokers with a history of 46.9±23.8 pack-years and a mean body mass index (BMI) of 29.0±21.3 kg·m^−2^. A total of 55.6% were at Global Initiative for Chronic Obstructive Lung Disease stage 3 or 4 and mean forced expiratory volume in 1 s (FEV~1~) was 48.7±13.2% predicted. Baseline HADS-A and HADS-D scores were 4.8±3.2 and 3.8±2.7, respectively, and MDD scores (PHQ-9) were 4.6±3.8, denoting low anxiety and depression levels in this cohort. Cognitive function (MoCA) scores were, on average, 25.6±3.1, which is just within the range of mild cognitive impairment ([table 1](#TB1){ref-type="table"}).

###### 

Baseline characteristics of the eligible subjects by self-management behaviour modification (SMBM) group (n=304)

  **Variables**                       **Total**     **T/O FDC (5/5 µg)+SMBM+ExT**   **T/O FDC (5/5 µg)+SMBM**   **T (5 µg)+SMBM**   **Placebo+SMBM**
  -------------------------------- --------------- ------------------------------- --------------------------- ------------------- ------------------
  **Subjects n**                         304                     76                            76                      76                  76
  **Demographics**                                                                                                                 
   Age years                          64.8±6.6                64.8±6.5                      64.9±6.9                65.1±6.4            64.4±6.6
   Males                             201 (66.1%)             45 (59.2%)                    48 (63.2%)              55 (72.4%)          53 (69.7%)
   BMI kg·m^2^                        29.0±21.3               28.1±5.3                      27.3±5.0                32.1±41.8           28.3±4.7
   Ever-smokers                      192 (63.2%)             48 (63.2%)                    47 (61.8%)              49 (64.5%)          48 (63.2%)
   Current smokers                   112 (36.8%)             28 (36.8%)                    29 (38.2%)              27 (35.5%)          28 (36.8%)
   Smoking history pack-years         46.9±23.8               46.1±24.2                     41.9±19.6               51.0±28.0          48.6±22.0
  **Symptoms and clinical data**                                                                                                   
   mMRC dyspnoea score                 1.3±0.9                 1.3±0.9                       1.3±0.9                 1.3±0.8            1.4±0.8
   Chronic bronchitis                143 (47.0%)             40 (52.6%)                    39 (51.3%)              34 (44.7%)          30 (39.5%)
   Sputum-producing cough            184 (60.5%)             49 (64.5%)                    43 (56.6%)              44 (57.9%)          48 (63.2%)
   Emphysema                         140 (46.1%)             38 (50.0%)                    33 (43.4%)              33 (43.4%)          36 (47.4%)
   SGRQ total score                   40.1±15.7               39.1±16.0                     40.6±17.1               39.1±15.3          41.7±14.5
   MoCA total score                   25.6±3.1                25.8±2.9                      25.3±3.4                25.4±3.0            25.8±3.1
   HADS-A score                        4.8±3.2                 4.7±3.4                       4.6±3.2                 5.2±3.2            4.9±3.2
   HADS-D score                        3.8±2.7                 3.7±3.0                       3.3±2.4                 4.2±2.8            4.1±2.4
   PHQ-9 total score                   4.6±3.8                 4.1±3.9                       4.2±3.4                 5.0±4.0            5.0±3.8
  **Lung function**                                                                                                                
   FEV~1~ L                            1.4±0.5                 1.3±0.5                       1.4±0.4                 1.4±0.4            1.4±0.5
   FEV~1~ % predicted                 48.7±13.2               49.1±13.3                     49.6±12.5               48.8±13.9          47.2±13.3
   FEV~1~/FVC %                       47.0±10.5               46.5±9.8                      48.7±11.8               46.8±9.9           45.9±10.3
   COPD GOLD stages 1--2             129 (42.4%)             35 (46.1%)                    34 (44.7%)              30 (39.5%)          30 (39.5)
   COPD GOLD stages 3--4             169 (55.6%)             40 (52.6%)                    38 (50.0%)              46 (60.5%)          45 (59.2)
  **Exercise function**                                                                                                            
   ESWT                                                                                                                            
    Walk distance m                  404.6±290.1             428.9±335.2                   436.8±300.2             388.9±265.4        363.8±252.0
    Walk duration min                  4.9±3.3                 5.3±3.8                       5.2±3.4                 4.8±3.0            4.5±3.0
    Shuttles                          40.5±29.0               42.9±33.5                     43.7±30.0               38.9±26.5          36.4±25.2
   Walk distance in 6MWT m           448.2±101.2             435.9±106.6                   458.0±100.4             450.2±94.7         448.7±103.6
  **Activity monitor/pedometer**                                                                                                   
   Steps per day                    5423.1±2820.2           5590.2±2683.4                 5723.2±3065.9           5162.6±2767.9      5223.7±2769.6
   Walking duration min               67.0±32.3               68.4±30.4                     69.9±36.3               64.5±31.0          65.3±31.7
   Walking intensity ×*g*              0.2±0.0                 0.2±0.0                       0.2±0.0                 0.2±0.0            0.2±0.0

Data are presented as mean±[sd]{.smallcaps} unless otherwise stated. p-values were obtained by performing ANOVA or Kruskal--Wallis test for continuous variable and Chi-Square test for category variables. T: tiotropium; O: olodaterol; FDC: fixed-dose combination; ExT: exercise training; BMI: body mass index; mMRC: modified Medical Research Council; SGRQ: St George\'s Respiratory Questionnaire; MoCA: Montreal Cognitive Assessment; HADS: Hospital Anxiety and Depression Scale; A: anxiety; D: depression; PHQ: Patient-Health Questionnaire; FEV~1~: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative for Chronic Obstructive Lung Disease; ESWT: endurance shuttle walk test; 6MWT: 6-min walk test.

Changes in psychological and cognitive outcomes after 12 weeks {#s3b}
--------------------------------------------------------------

There were no significant between-group differences in any outcome with the exception of cognitive function, where significantly greater increases in cognitive function (MoCA total scores) were observed between the SMBM+T and SMBM+T/O treatment groups compared with the SMBM+P group ([table 2](#TB2){ref-type="table"}). As a result, we conducted all further analyses on the sample as a cohort, adjusting for treatment group.

###### 

The changes in psychological and cognitive outcomes after 12 weeks by self-management behaviour modification (SMBM) group

  **Variables**               **Total (n=262)**   **T/O FDC (5/5 µg)+SMBM+ExT (n=65)**   **T/O FDC (5/5 µg)+SMBM (n=69)**   **T (5 µg)+SMBM (n=64)**   **Placebo+SMBM (n=64)**   **Four-group comparison p-value**                                                                        
  -------------------------- ------------------- -------------------------------------- ---------------------------------- -------------------------- ------------------------- ----------------------------------- ------------ -------------------- ------------ ---------------------- -------
  **MoCA total score**^\#^        25.5±3.2                   27.5±2.6\*\*\*                          25.7±3.0                    27.7±2.5\*\*\*               25.3±3.5                  27.5±2.6\*\*\*^,¶^            25.2±3.1    27.4±2.5\*\*\*^,+^    25.8±3.2    27.2±2.7\*\*\*^,¶,+^   0.043
  **MoCA \<26**^\#^              116 (44.3%)                49 (19.0%)\*\*\*                        26 (40.0%)                  11 (16.9%)\*\*\*             34 (49.3%)                  11 (15.9%)\*\*\*            31 (48.4%)    13 (20.6%)\*\*\*    25 (39.1%)      14 (23.0%)\*\*      0.106
  **HADS-A score**                 4.9±3.3                   3.8±3.0\*\*\*                           4.9±3.4                      3.8±2.5\*\*                  4.5±3.2                     3.1±3.2\*\*\*              5.0±3.3       3.9±3.0\*\*\*       5.0±3.3           4.3±3.3          0.225
  **HADS-A ≥8**                  51 (19.5%)                  31 (12.0%)\*\*                         10 (15.4%)                      6 (9.2%)                 11 (15.9%)                     10 (14.5%)               17 (26.6%)     8 (12.7%)\*\*      13 (20.3%)        7 (11.5%)         0.676
  **HADS-D score**                 3.8±2.6                   3.1±2.6\*\*\*                           3.8±3.1                     2.6±2.3\*\*\*                 3.2±2.3                       2.6±2.4\*                3.8±2.7          3.4±2.9          4.2±2.3           3.6±2.8          0.288
  **HADS-D ≥8**                   24 (9.2%)                    20 (7.8%)                            7 (10.8%)                       3 (4.6%)                  3 (4.3%)                       4 (5.8%)                8 (12.5%)        7 (11.1%)         6 (9.4%)          6 (9.8%)         0.269
  **PHQ-9 total score**            4.5±3.7                   3.1±3.3\*\*\*                           4.4±4.0                     2.7±2.8\*\*\*                 3.9±3.1                     2.7±3.0\*\*\*              4.4±3.6       3.1±3.2\*\*\*       5.1±4.0          3.8±3.9\*         0.253
  **PHQ-9 ≥5**                   98 (37.4%)                 62 (24.0%)\*\*\*                        27 (41.5%)                  12 (18.5%)\*\*\*             22 (31.9%)                   13 (18.8%)\*\*             24 (37.5%)       16 (25.4%)       25 (39.1%)        21 (34.4%)        0.282

Data are presented as mean±[sd]{.smallcaps} unless otherwise stated. p-values were obtained by performing a generalised estimating equation (GEE) model with type III likelihood ratio statistics *via* normal distribution with a logarithmic link function for continuous variables, and binary distribution with a logit link function for category variables. For the four-group comparison, we used a GEE model with repeated statement to test the time×group interaction term and estimated whether the average change in the outcome from baseline to week 12 differed in the two groups. T: tiotropium; O: olodaterol; FDC: fixed-dose combination; ExT: exercise training; MoCA: Montreal Cognitive Assessment; HADS: Hospital Anxiety and Depression Scale; A: anxiety; D: depression; PHQ: Patient-Health Questionnaire. ^\#^: means and proportions adjusted for correlation between repeated measures. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001, comparing baseline and week 12 after Tukey adjustment. ^¶^ and ^+^: means with same symbol are significantly different from each other in terms of the average change in the outcome from baseline to week 12 (p\<0.05).

Independent of treatment group and other covariates, HADS-A, HADS-D and PHQ-9 scores all decreased significantly from baseline to post-treatment (p\<0.001) ([table 2](#TB2){ref-type="table"} and [figure 2](#F2){ref-type="fig"}). However, average baseline levels of psychological distress were quite low (all in the normal range) ([table 2](#TB2){ref-type="table"}). Therefore, changes in the proportion of patients exhibiting clinically significant levels of anxiety (HADS-A ≥8), depression (HADS-D ≥8) and MDD symptoms (PHQ-9 ≥5) were also analysed. Treatment was associated with a significant reduction in the proportion of patients exhibiting clinically significant anxiety and MDD (p\<0.001) ([figure 3](#F3){ref-type="fig"}). A similar pattern was observed for cognitive function, where scores on the MoCA increased significantly (denoting improved cognitive function) from pre- to post-treatment ([table 2](#TB2){ref-type="table"} and [figure 3](#F3){ref-type="fig"}). Like with the psychological outcomes, we found that that the proportion of patients scoring within the range of mild cognitive impairment (MoCA \<26) improved significantly from pre- (44%) to post-treatment (19%) (p\<0.001) ([figure 2](#F2){ref-type="fig"}).

![Changes in psychological and cognitive outcomes after 12 weeks of with tiotropium (T), T/olodaterol (O) or placebo. a) Total; b) self-management behaviour modification (SMBM)+T/O+exercise training; c) SMBM+T/O; d) SMBM+T; e) SMBM+placebo. MoCA: Montreal Cognitive Assessment; HADS: Hospital Anxiety and Depression Scale; A: anxiety; D; depression; PHQ: Patient-Health Questionnaire. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001, by comparing baseline and week 12 after Tukey adjustment; ^\#^: p\<0.05, SMBM+T/O *versus* SMBM+placebo; ^¶^: p\<0.05 SMBM+T *versus* SMBM+placebo.](00013-2019.02){#F2}

![Proportion of patients experiencing changes in psychological and cognitive outcomes after 12 weeks of treatment with tiotropium (T), T/olodaterol (O) or placebo. a) Total; b) self-management behaviour modification (SMBM)+T/O+exercise training; c) SMBM+T/O; d) SMBM+T; e) SMBM+placebo. MoCA: Montreal Cognitive Assessment; HADS: Hospital Anxiety and Depression Scale; A: anxiety; D; depression; PHQ: Patient-Health Questionnaire. \*\*: p\<0.01; \*\*\*: p\<0.001.](00013-2019.03){#F3}

Association between increases in physical activity and exercise capacity and changes in psychological and cognitive outcomes {#s3c}
----------------------------------------------------------------------------------------------------------------------------

Independent of treatment group and other covariates, we observed a significant association between increases in all physical activity variables and all but one exercise capacity variable (ESWT walk duration) and improvements (decreases) in depression scores (HADS-D and PHQ-9) after adjustment for covariates ([table 3](#TB3){ref-type="table"}). Every 100-step increase per day was associated with a 0.009-point reduction in the HADS-D (p=0.003) and a 0.01-point reduction in the PHQ-9 (p=0.012). Every 10-min increase in walk duration was associated with a 0.08-point reduction in the HADS-D (p=0.003) and a 0.08-point reduction in the PHQ-9 (p=0.033). Every 1-point increase in walking intensity was associated with a 14.94-point reduction in the HADS-D (p\<0.0001) and a 10.31-point reduction in the PHQ-9 (p=0.032). Similar to the physical activity variables, every 10-m increase in ESWT distance was associated with a 0.007-point reduction in the HADS-D (p=0.005) and 0.007-point reduction in PHQ-9 (p=0.049); every 1-min increase in ESWT duration was associated with a 0.05-point reduction in the HADS-D (p=0.016); every 5-point increase in ESWT number was associated with a 0.04-point reduction in the HADS-D (p=0.004) and 0.03-point reduction in the PHQ-9 (p=0.046); and every 10-m increase in 6MWT distance was associated with a 0.04-point reduction in the HADS-D (p\<0.001) and a 0.05-point reduction in the PHQ-9 (p=0.001).

###### 

The association between psychological and cognitive outcomes and physical activity (PA) and exercise capacity variables using multiple mixed effect random models

  **Independent variables**                          **MoCA**^\#^ **total score**   **HADS-A score**       **HADS-D score**        **PHQ-9 total score**                                                                        
  ------------------------------------------------- ------------------------------ ------------------ --------------------------- ----------------------- ----------------------------- --------- ----------------------------- -------
  **PA variables**                                                                                                                                                                                                              
   Steps per day per  increased 100 steps             −0.0028 (−0.0095--0.0038)          0.407         −0.0038 (−0.0115--0.0038)           0.328           −0.0092 (−0.0153-- −0.0030)    0.003    −0.0107 (−0.0191-- −0.0023)   0.012
   Walking duration  mins per increased  10 mins        −0.038 (−0.099--0.022)           0.216          −0.030 (−0.099--0.040)             0.402            −0.084 (−0.140-- −0.028)      0.003     −0.083 (−0.159-- −0.007)     0.033
   Walking intensity per  increased 1 point              5.55 (−1.98--13.08)             0.148          −10.94 (−19.54-- −2.33)            0.013             −14.94 (−21.90-- −7.97)     \<0.001     −10.31 (−19.71-- −0.90)     0.032
  **Exercise capacity**                                                                                                                                                                                                         
   ESWT                                                                                                                                                                                                                         
    Walk distance per   increased 10 m                  0.003 (−0.002--0.009)            0.218           0.001 (−0.005--0.007)             0.848            −0.007 (−0.012-- −0.002)      0.005     −0.007 (−0.013-- −0.000)     0.049
    Walk duration mins   per increased   1 min            0.03 (−0.01--0.08)             0.187            0.01 (−0.05--0.06)               0.794              −0.05 (−0.09-- −0.01)       0.016        −0.05 (−0.11--0.01)       0.096
    Number of   shuttles per   increased 5 points       0.016 (−0.011--0.042)            0.253           0.004 (−0.027--0.034)             0.816            −0.036 (−0.061-- −0.011)      0.004     −0.034 (−0.068-- −0.001)     0.046
   Walk distance in  6MWT per increased                  0.035 (0.011--0.058)            0.005          −0.007 (−0.034--0.021)             0.639            −0.038 (−0.060-- −0.016)     \<0.001    −0.049 (−0.078-- −0.019)     0.001
    10 m                                                                                                                                                                                                                        

Models adjusted for baseline age, sex, body mass index, smoking pack-years, % predicted forced expiratory volume in 1 s, treatment group and time variable week. MoCA: Montreal Cognitive Assessment; HADS: Hospital Anxiety and Depression Scale; A: anxiety; D: depression; PHQ: Patient-Health Questionnaire; ESWT: endurance shuttle walk test; 6MWT: 6-min walk test.^\#^: adjusted for correlation between repeated measures.

Associations between physical activity, exercise capacity changes, and improvements in anxiety and cognitive function were less consistent. HADS-A scores decreased by 10.94 points in association with every 1-point increase in daily walking intensity (p=0.013), and MoCA scores increased by 0.04 with every 10-m increase in distanced walked during the 6MWT (p=0.005).

Discussion {#s4}
==========

This study assessed the effects of a SMBM programme alone or in combination with bronchodilator therapy (tiotropium or T/O), with or without ExT, on psychological and cognitive outcomes in patients with COPD in a secondary analysis of data from the PHYSACTO trial. The only between-group differences were observed for cognitive function, where greater increases in MoCA total scores were observed in the SMBM+T and SMBM+T/O groups (but not the SMBM+T/O+ExT group) compared with the SMBM+P group. Contrary to our hypotheses, this suggests that being exposed to ExT does not seem to afford any additional benefit for cognitive function over and above SMBM (which emphasised increasing daily levels of physical activity)+bronchodilator therapy alone. This contributed to treating the sample as a cohort and conducting all further analyses adjusting for treatment group. These analyses revealed that levels of anxiety, depression, MDD symptoms and cognitive function all showed statistically and clinically significant improvements from pre- to post-treatment, irrespective of treatment group, which is consistent with previous reports \[[@C35], [@C36]\].

Anxiety improved with greater increases in physical activity, cognitive function improved with greater increases in exercise capacity, and depression improved with greater increases in both physical activity and exercise capacity. Findings of improved cognitive function associated with increased exercise capacity are consistent with previous exercise intervention studies in patients with chronic disease \[[@C22]\] and patients with COPD \[[@C25], [@C36]\]. Results linking increased exercise capacity to improvements in depression are also consistent with previous reports, where studies have reported improvements in depression following pulmonary rehabilitation programmes \[[@C37]\]. Depression also improved with increases in physical activity, as did anxiety, in line with previous reports linking physical activity to improvements in depression and anxiety \[[@C38], [@C39]\].

Although this study was not designed to explore the mechanisms responsible for the positive associations between increases in physical activity/exercise capacity and differential improvements in psychological and cognitive outcomes, it is possible that only patients who were able to achieve certain thresholds of physiological arousal (*i.e.* enough to improve exercise capacity) experienced improvements in cognitive function with increased exercise capacity. Previous research has shown that engaging in at least 45--60 min of moderate-intensity aerobic exercise about three times per week \[[@C40]\] affects the aspects of brain structure and function associated with cognition, including increasing cerebral blood flow \[[@C41]\] and stimulating central neurotransmitter release \[[@C42]\]. Cognitive function did not seem to improve with increasing physical activity, suggesting that being physically active alone may not produce sufficient physiological arousal to impact the biological processes associated with cognitive performance. This is consistent with the results of at least one prospective study that showed that increasing levels of physical activity among patients with COPD undergoing pulmonary rehabilitation did not translate into increases in exercise capacity \[[@C38]\].

Conversely, increases in physical activity, and not exercise capacity, were associated with improvements in anxiety. Highly anxious patients typically avoid engaging in situations or behaviours that they believe will cause psychological or physical discomfort \[[@C43]\]. Patients with COPD who have high anxiety levels have been shown to avoid social situations due to fears of being embarrassed by their symptoms, or of engaging in physical activity for fear of exacerbating symptoms or experiencing pain \[[@C44]\]. It is therefore possible that patients who successfully increase their daily level of physical activity learn through gradual exposure that increasing physical activity is safe and achievable, thereby reducing overall anxiety levels.

Depressive symptoms and MDD scores improved as a result of both increases in physical activity and increases in exercise capacity. This finding suggests that depression/MDD may improve through both biological and behavioural pathways, which is consistent with the major theories and treatments of depression \[[@C45]\]. Depression is thought to occur as a result of several neurophysiological factors, including hormonal and neurotransmitter imbalances causing dysregulations in emotional processing and behavioural activation \[[@C46]\]. Like cognitive function, it is possible that achieving the thresholds of physiological arousal sufficient to improve exercise capacity can result in improvements in depression/MDD. However, the fact that physical activity also improved depression/MDD scores is consistent with behavioural theories of depression that link depression to maladaptive thoughts and behaviours \[[@C47]\]. Unlike exercise capacity, physical activity is a behaviour that tends be self-directed and motivated by psychological factors such as beliefs, self-efficacy and outcome expectancies \[[@C48]\]. The behavioural activation required to engage in higher levels of physical activity may have been sufficient to change beliefs and improve self-efficacy, which may have in turn resulted in improvements in depressed mood.

This study has some limitations. First, the results should be interpreted with caution as this was a secondary analysis of data from a study with another primary objective, so was not specifically powered for these outcomes. Second, a treatment-free control group was not included, therefore the extent to which psychological and cognitive outcomes may have improved spontaneously cannot be ruled out. However, previous research has shown that cognitive function among older adults tends to be degenerative and rarely improves outside of treatment \[[@C49]\]. While depression and anxiety levels can vary over time independently of formal intervention, it is less common to see such a consistent pattern of clinically significant changes outside of treatment \[[@C50]\]. Our psychological outcomes were self-reported, not objectively assessed (*i.e.* using a psychiatric interview) and may be subject to self-report bias. Further, baseline levels of anxiety and depression on the HADS and PHQ-9 were extremely low, suggesting that a possible regression to the mean effect could have been observed post-intervention. However, we did use valid and reliable self-reported questionnaires that have established clinical cut-offs. This allows for the classification of clinically significant levels of psychological distress which we were able to show shifted in a clinically meaningful way post-treatment. The 12-week duration of the study was also very short and may have limited our ability to detect larger effects on outcomes (*e.g.* cognitive function) that may take more time to change. However, it is noteworthy that despite the short intervention period, we still observed both statistically and clinically significant improvements on depression, anxiety and cognitive function. Lastly, the MoCA may be subject to some practice effects. However, data suggest there are little-to-no practice effects when the MoCA is administered at intervals ≥3 months, which is less than the pre- to post-treatment assessment interval in the present study. To account for this, we adjusted for repeated assessments, and even when practice effects are observed, they tend to account for \<10% of scores \[[@C34]\].

Despite some limitations, this study has several notable strengths. It includes a large sample of well-characterised patients with COPD from 12 countries, which increases the generalisability of the results. The interventions (including SMBM) were carefully implemented: all case managers received standardised training on the protocol and its delivery, and underwent multiple fidelity assessments (*i.e.* self-assessments of performance, and expert-rater assessments of audio-taped individual and group sessions). Only valid and reliable psychological and cognitive measures were used, and the administering personnel, who were blind to treatment group, received standardised training and ongoing supervision. Physical activity was assessed objectively using accelerometers, and all results were adjusted for important covariates, including age, sex, BMI, smoking pack-years, pulmonary function (FEV~1~ % predicted) and baseline levels of each outcome variable, attesting to the robustness of the findings.

In summary, our data indicate that SMBM aimed at improving daily physical activity with or without bronchodilators (tiotropium or T/O), with or without ExT, was associated with both statistically and clinically significant improvements in psychological cognitive functioning in moderate--severe COPD patients in the PHYSACTO study. However, anxiety improved with greater increases in physical activity, cognitive function improved with greater increases in exercise capacity, and depression improved with increases in either physical activity or exercise capacity. Although this was a secondary analysis of data from a study with another primary objective, the overall pattern of results indicates that interventions that increase daily physical activity and/or exercise capacity may be beneficial for improving psychological and cognitive outcomes in patients with COPD and provides additional evidence of the importance of increasing access to physical activity/exercise-based interventions in patients with COPD.
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